• Corpus ID: 34066946

Update on methotrexate as the anchor drug for rheumatoid arthritis.

  title={Update on methotrexate as the anchor drug for rheumatoid arthritis.},
  author={Theodore Pincus and Kathryn A. Gibson and Isabel Castrej{\'o}n},
  journal={Bulletin of the Hospital for Joint Disease},
  volume={71 Suppl 1},
Methotrexate has become the "anchor drug" for rheumatoid arthritis (RA), taken by many more patients than any other disease modifying anti-rheumatic drug (DMARD) or biological agent. Methotrexate has greater efficacy and effectiveness than any other non-biologic DMARD, and greater tolerability and safety than other DMARDs. The efficacy of methotrexate is comparable to biologic agents in parallel clinical trials of DMARD-naïve patients. Adequate responses to methotrexate monotherapy or… 

Figures and Tables from this paper

Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis

To improve the response to oral MTX, a high initial dose should be administered followed by rapid titration, and this approach does not appear to compromise safety or tolerability for patients.

Does methotrexate cause interstitial lung disease in rheumatoid arthritis: What is the evidence?

  • A. Malaviya
  • Medicine
    International journal of rheumatic diseases
  • 2020
Low-dose methotrexate (LD-MTX) is presently the mainstay of treatment of rheumatoid arthritis and its efficacy in treating several additional systemic immunoinflammatory rheumatic diseases (SIRDs) has broadened its use worldwide.

Study on the relationship between low-dose methotrexate and the concentration and efficacy of polyglutamated methotrexate in the treatment of rheumatoid arthritis

Although there are a variety of biological DMARD developed, MTX remains the main drug for RA patients, and 2018 Chinese rheumatoid arthritis diagnosis and treatment guidelines first recommended MTX as a singleDrug for RA.

Biologic monotherapy in the treatment of rheumatoid arthritis

In daily practice, approximately 30% of patients with biological therapy receive no concomitant DMARD according to the register data, and a discontinuation of the drug is necessary.

Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis

A dose-conversion method based on the BA of MTX from oral and SC administration is established, and unlike the exposure limitations of oral MTX, dose-proportional exposure was seen with SC MTX.

Methotrexate intolerance in Rheumatoid Arthritis

A compilation of the available literature on Methotrexate intolerance in Rheumatoid Arthritis and strategies to mitigate this effect is presented.

Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.

There is an increasing evidence of the potential of some bDMARDs and ts DMARDs in monotherapy, which may become a considerable and realistic option in RA patients.

Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.

Combinations of methotrexate with other non-biologic DMARDs and glucocorticoids, toward a target of low disease activity or remission, may improve outcomes for patients with RA at levels similar to biologic agents in many patients.

Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy

  • Cecli Zenuk
  • Medicine
    Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
  • 2018
The prognosis for patients with RA has dramatically improved over the past 2 decades due to multiple factors, primarily, earlier diagnosis, treatment targeted to remission or low disease activity, the use of conventional synthetic DMARD in combination and the availability of biologic DMARD (bDMARD) and targeted syntheticDMARD (tsDMARD).

Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.

The two major advances over the 1990s in the treatment of rheumatoid arthritis were a shift in strategy from a "pyramid", in which disease modifying anti-rheumatic drugs were deferred for several years, to widespread acceptance of methotrexate as the DMARD with the most long-term effectiveness and safety.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

For patients with active RA in its early stages, combination therapy with MTX and infliximab provides greater clinical, radiographic, and functional benefits than treatment withMTX alone.

Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis

A systematic review of trials that comparedDMARDs in adults with rheumatoid arthritis found few direct comparisons of different agents but no important differences among synthetic DMARDs or antitumor necrosis factor drugs.

Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature.

It is suggested that LE elevations during MTX therapy are a frequent but transient problem, that serial abnormal LE tests might be associated with liver pathology, but that cirrhosis is relatively rare.

Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

Etanercept as monotherapy was safe and was superior to MTX in reducing disease activity, arresting structural damage, and decreasing disability over 2 years in patients with early, aggressive RA.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

The addition of adalimumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-term MTX therapy in patients with active RA provided significant, rapid, and sustained improvement in disease activity over 24 weeks compared with MTX plus placebo.

Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis.

OBJECTIVE The relative high cost and potential side effects mandate careful scrutiny as to when tumor necrosis factor alpha (TNF) inhibitors should be used in everyday practice. We surveyed how TNF

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.

Of the commonly used second-line drugs, AUR is the weakest, and injectable gold is the most toxic, and agents introduced in the future will be compared with these drugs.

Rheumatoid Arthritis: Treat Now, Not Later!

It is suggested that the opportunity to intervene and possibly modify the course of disease before structural damage occurs may appear earlier rather than later, and conventional second-line therapies do not generally alleviate or heal radiographic damage.